Literature DB >> 31404008

Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors: A Prospective Nationwide Multicenter Study.

Yukinori Kurokawa1, Hiroya Takeuchi2, Yuichiro Doki1, Shinji Mine3, Masanori Terashima4, Takushi Yasuda5, Kazuhiro Yoshida6, Hiroyuki Daiko7, Shinichi Sakuramoto8, Takaki Yoshikawa9, Chikara Kunisaki10, Yasuyuki Seto11, Shigeyuki Tamura12, Toshio Shimokawa13, Takeshi Sano3, Yuko Kitagawa14.   

Abstract

OBJECTIVE: The aim of the study was to determine the optimal extent of lymph node dissection for the 2 histological types of esophagogastric junction (EGJ) tumors based on the incidence of metastasis in a prospective nationwide multicenter study.
BACKGROUND: Because most previous studies were retrospective, the optimal surgical procedure for EGJ tumors has not been standardized.
METHODS: Patients with cT2-T4 adenocarcinoma or squamous cell carcinoma located within 2.0 cm of the EGJ were enrolled before surgery. Surgeons dissected all lymph nodes prespecified in the protocol, using either the abdominal transhiatal or right transthoracic approach. The primary endpoint was the metastasis rate of each lymph node. Lymph nodes were classified according to metastasis rate, as follows: category-1 (strongly recommended for dissection), rate more than 10%; category-2 (weakly recommended for dissection), rate from 5% to 10%; and category-3 (not recommended for dissection), rate less than 5%.
RESULTS: Between 2014 and 2017, 1065 patients with EGJ tumor were screened, and 371 were enrolled. Among 358 patients who underwent surgical resection, category-1 nodes included abdominal stations 1, 2, 3, 7, 9, and 11p, whereas category-2 nodes included abdominal stations 8a, 19, and lower mediastinal station 110. If esophageal involvement exceeded 2.0 cm, station 110 was assigned to category-1. Among 98 patients who had either adenocarcinoma with esophageal involvement over 3.0 cm or squamous cell carcinoma, there were no category-1 nodes in the upper/middle mediastinal field, whereas category-2 nodes included upper mediastinal station 106recR and middle mediastinal station 108. When esophageal involvement exceeded 4.0 cm, station 106recR was assigned to category-1.
CONCLUSION: The study accurately identified the distribution of lymph node metastases from EGJ tumors and the optimal extent of subsequent lymph node dissection.
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 31404008     DOI: 10.1097/SLA.0000000000003499

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  31 in total

Review 1.  Esophagogastric junction adenocarcinomas: individualization of resection with special considerations for Siewert type II, and Nishi types EG, E=G and GE cancers.

Authors:  Arnulf H Hölscher; Simon Law
Journal:  Gastric Cancer       Date:  2019-11-06       Impact factor: 7.370

2.  Is the length of esophageal invasion only associated with mediastinal nodal metastasis from adenocarcinoma of the esophagogastric junction (Siewert type II and III) after neo-adjuvant chemoradiotherapy?

Authors:  Shinji Mine
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

3.  Side-overlap esophagogastric tube (SO-EG) reconstruction after minimally invasive Ivor Lewis esophagectomy or laparoscopic proximal gastrectomy for cancer of the esophagogastric junction.

Authors:  Hisahiro Hosogi; Masazumi Sakaguchi; Daisuke Yagi; Ryohei Onishi; Yasuhiro Hashimoto; Yoshiharu Sakai; Seiichiro Kanaya
Journal:  Langenbecks Arch Surg       Date:  2021-11-13       Impact factor: 3.445

4.  Letter to Editor of Annals of Surgical Oncology Concerning "Esophagectomy or Total Gastrectomy for Siewert 2 Gastroesophageal Junction (GEJ) Adenocarcinoma? A Registry-Based Analysis".

Authors:  Fabio Carboni; Mario Valle
Journal:  Ann Surg Oncol       Date:  2021-10-22       Impact factor: 5.344

5.  Prediction of tissue origin of adenocarcinomas in the esophagogastric junction by DNA methylation.

Authors:  Chun-Dong Zhang; Hideyuki Takeshima; Shigeki Sekine; Satoshi Yamashita; Yu-Yu Liu; Naoko Hattori; Hiroyuki Abe; Hiroharu Yamashita; Masahide Fukuda; Yu Imamura; Tetsuo Ushiku; Hitoshi Katai; Hiroshi Makino; Masayuki Watanabe; Yasuyuki Seto; Toshikazu Ushijima
Journal:  Gastric Cancer       Date:  2021-09-23       Impact factor: 7.370

6.  Laparoscopic vs. open lower mediastinal lymphadenectomy for Siewert type II/III adenocarcinoma of esophagogastric junction: An exploratory, observational, prospective, IDEAL stage 2b cohort study (CLASS-10 study).

Authors:  Shuangxi Li; Xiangji Ying; Fei Shan; Yongning Jia; Zhemin Li; Kan Xue; Rulin Miao; Yinkui Wang; Zhaode Bu; Xiangqian Su; Ziyu Li; Jiafu Ji
Journal:  Chin J Cancer Res       Date:  2022-08-30       Impact factor: 4.026

7.  Safety and efficacy of preoperative indocyanine green fluorescence marking in laparoscopic gastrectomy for proximal gastric and esophagogastric junction adenocarcinoma (ICG MAP study).

Authors:  Takeshi Omori; Hisashi Hara; Naoki Shinno; Masaaki Yamamoto; Takashi Kanemura; Tomohira Takeoka; Hirofumi Akita; Hiroshi Wada; Masayoshi Yasui; Chu Matsuda; Junichi Nishimura; Masayuki Ohue; Masato Sakon; Hiroshi Miyata
Journal:  Langenbecks Arch Surg       Date:  2022-10-13       Impact factor: 2.895

8.  Continuous Recurrent Laryngeal Nerve Monitoring During Single-Port Mediastinoscopic Radical Esophagectomy for Esophageal Cancer.

Authors:  Shuhei Komatsu; Tomoki Konishi; Daiki Matsubara; Koji Soga; Katsumi Shimomura; Jun Ikeda; Fumihiro Taniguchi; Hitoshi Fujiwara; Yasuhiro Shioaki; Eigo Otsuji
Journal:  J Gastrointest Surg       Date:  2022-10-11       Impact factor: 3.267

9.  Current status and challenges in sentinel node navigation surgery for early gastric cancer.

Authors:  Satoru Matsuda; Tomoyuki Irino; Hirofumi Kawakubo; Hiroya Takeuchi; Yuko Kitagawa
Journal:  Chin J Cancer Res       Date:  2021-04-30       Impact factor: 5.087

10.  Oncologic Feasibility of Proximal Gastrectomy in Upper Third Advanced Gastric and Esophagogastric Junctional Cancer.

Authors:  Won-Gun Yun; Myung-Hoon Lim; Sarah Kim; Sa-Hong Kim; Ji-Hyeon Park; Seong-Ho Kong; Do Joong Park; Hyuk-Joon Lee; Han-Kwang Yang
Journal:  J Gastric Cancer       Date:  2021-06-23       Impact factor: 3.720

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.